Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

Home
/
update
/
details

Nanostics and OncoHelix Partner to Launch AI-Driven Prostate Cancer Test in the Middle East

NextEdge Admin

28 Sep 2024

2 min 32 sec

Nanostics and OncoHelix have partnered to introduce Nanostics’ ClarityDX Prostate, a prostate cancer blood test, to healthcare providers and men in the Middle East. OncoHelix will offer the test through an Abu Dhabi-based laboratory, operated in partnership with UAE healthcare group Burjeel Holdings.

ClarityDX Prostate combines clinical data with AI-powered learning models to deliver a personalized risk score based on prostate-specific antigen (PSA) levels and digital rectal examination (DRE) results. PSA and DRE are standard tools for early detection of prostate cancer, with elevated PSA levels potentially signaling cancer or other prostate issues, and DRE allowing a physical assessment of the prostate for abnormalities.

This advanced diagnostic tool aims to help men and healthcare providers make informed decisions about whether to proceed with a biopsy. By offering data-driven insights, ClarityDX Prostate could reduce unnecessary biopsies, with a study published in *npj Digital Medicine* showing 95% sensitivity, 35% specificity, and the potential to avoid up to 35% of unnecessary prostate biopsies.

OncoHelix’s CEO, Faisal Khan, expressed excitement about the partnership, emphasizing the importance of the tool in enabling earlier detection and more targeted treatment for men at risk of aggressive prostate cancer in the Middle East.

This development follows the recent launch of ClarityDX Prostate in Alberta, Canada, and a deal with Protean BioDiagnostics to market the tool in the US. The AI-driven test is part of a growing trend in cancer detection, with companies like Cortechs.ai also introducing AI-powered solutions, such as OnQ Prostate, to enhance prostate cancer detection through advanced imaging software.